Printer Friendly

PROSORBA COLUMN TREATMENTS RESULT IN LONG-TERM CLEARANCE OF AUTOIMMUNE BLEEDING DISORDER

 PROSORBA COLUMN TREATMENTS RESULT IN LONG-TERM
 CLEARANCE OF AUTOIMMUNE BLEEDING DISORDER
 SEATTLE, May 1 /PRNewswire/ -- IMRE Corporation (NASDAQ: IMRE) announced today that following treatments with its Prosorba (R) column, 46 percent of 72 patients with the autoimmune bleeding disorder, immune thrombocytopenic purpura (ITP), had clinical improvements.
 Approximately 79 percent of responding patients had long-term responses: up to two years and counting. Most of the patients had failed several other anti-autoimmune treatments prior to this study. Clinical improvements in patients are supported by laboratory data which show clearance or decreases in the autoimmunity-causing antibodies.
 "The importance of this report rests in the observation that it may now be possible to change, i.e., modulate the 'out-of-control' immune response system in the autoimmune patient," said Dr. Frank R. Jones, chairman and chief executive officer of IMRE. "This is why we are expanding our studies to include other autoimmune diseases such as rheumatoid arthritis."
 The multicenter evaluation of the Prosorba column as a treatment for ITP is reported in today's issue of the journal Blood. ITP affects about 25,000 people in the United States and a larger number on a worldwide basis. Since the disease is a blood clotting disorder, patients can suffer from easy bruisability to severe life-threatening hemorrhaging, particularly in the head or intestinal regions. The Prosorba column received approval for marketing by the Food and Drug Administration for the treatment of ITP in late 1987. A wide range of other applications is being explored by the company.
 During the study, an average of six treatments were given over a two-to-three week period. There were no side effects in about 70 percent of the treatments. The mild to moderate side effects noted were easily managed.
 The Prosorba column, which was developed and patented by IMRE scientists, is a disposable one-time use cylindrical canister about three inches in diameter and three inches long. It contains solid granules of silica which have a molecule bound to them which can remove immune suppressor molecules from a patient's blood plasma. Following removal of this immune suppressor, the body's immune system acts more normally and combats the disease. In the procedure, the patient's plasma is separated from the blood cells, passed through the Prosorba column, re-mixed with the cells are re-infused into the same patient, a process that takes about two hours.
 In the article entitled "Experience with Protein A-Immunoadsorption in Treatment-Resistant Adult Immune Thrombocytopenic Purpura," the authors, who are from several institutions, conclude that the Prosorba column treatment has merit in the treatment of the autoimmune disease ITP.
 IMRE Corporation is a medical products company that is the leader in the field of immunoadsorption treatments. The company's first product, the Prosorba column, has been approved by the Food and Drug Administration for treatment of idiopathic thrombocytopenic purpura, an immune-related bleeding disorder. The company is currently conducting clinical trials in rheumatoid arthritis, other autoimmune diseases, and certain cancers.
 -0- 5/1/92
 /CONTACT: Lois Yoshida of IMRE, 206-298-9400/
 (IMRE) CO: IMRE Corporation ST: Washington IN: MTC SU:


AH-CK -- NY025 -- 5410 05/01/92 10:50 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 1, 1992
Words:511
Previous Article:THE ST. PAUL COMPANIES MAY REPURCHASE UP TO 5 PERCENT OF OUTSTANDING COMMON STOCK
Next Article:NORTH AMERICAN VENTURES, INC. PROPOSES NAME CHANGE AND REVERSE STOCK SPLIT


Related Articles
IMRE ANNOUNCES PUBLICATION IN NEW ENGLAND JOURNAL OF MEDICINE
IMRE CORPORATION RESUMES SHIPMENT OF PRODUCT
FDA APPROVES IMRE'S NEW MANUFACTURING FACILITY
THE JOURNAL TRANSFUSION PUBLISHES ARTICLE ON TREATMENT OF REFRACTORINESS TO PLATELET TRANSFUSION WITH IMRE CORPORATION'S PROSORBA COLUMN
IMRE CORPORATION COMPLETES $2 MILLION PRIVATE OFFERING
THE LANCET PUBLISHES CASE STUDY ON EFFECTIVENESS OF IMRE'S PROSORBA(R) COLUMN
JOURNAL OF CLINICAL APHERESIS PUBLISHES RESULTS OF TREATMENT OF NERVOUS DISEASE WITH IMRE CORPORATION'S PROSORBA COLUMN
IMRE CLINICAL TRIAL CONFIRMS RESULTS OF INDEPENDENT RHEUMATOID ARTHRITIS STUDY
RHEUMATOID ARTHRITIS RESULTS FROM INDEPENDENT CLINICAL TRIAL OF PROSORBA COLUMN SHOW LONG-TERM EFFECTS
IMRE CORPORATION ANNOUNCES RHEUMATOID ARTHRITIS CLINICAL TRIAL APPROVED BY FDA

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters